title: Heliotherapy for Neonatal Hyperbilirubinemia in Southwest, Nigeria: A Baseline Pre-Intervention Study.
abstract: BACKGROUND
  A novel filtered-sunlight phototherapy (FSPT) device has been demonstrated to be safe and efficacious for treating infants with neonatal jaundice in resource-constrained tropical settings. We set out to provide baseline data for evaluating the clinical impact of this device in a referral pediatric hospital.
  
  
  METHODS
  We reviewed the medical records of infants admitted for neonatal hyperbilirubinemia in an inner-city Children's Hospital in Lagos, between January 2012 and December 2014 to determine the pattern, treatment and outcomes during the pre-intervention period. Factors associated with adverse outcomes were identified through multivariable logistic regression.
  
  
  RESULTS
  Of the 5,229 neonatal admissions over the period, a total of 1,153 (22.1%) were admitted for neonatal hyperbilirubinemia. Complete records for 1,118 infants were available for analysis. The incidence of acute bilirubin encephalopathy (ABE) and exchange transfusion (ET) were 17.0% (95% CI: 14.9%-19.3%) and 31.5% (95% CI: 28.8%-34.3%) respectively. A total of 61 (5.5%, 95% CI: 4.3%-6.9%) of the jaundiced infants died. Weight on admission, peak total serum bilirubin (TSB), sepsis and exposure to hemolytic products were predictive of ABE, while age on admission, peak TSB, ABO incompatibility and ABE were predictive of ET. Rhesus incompatibility, asphyxia, exposure to hemolytic substances and ABE were associated with elevated mortality risk, while ET was a protective factor. Lack of routine irradiance monitoring and steady energy supply were frequent challenges for conventional blue-light phototherapy.
  
  
  CONCLUSIONS
  Severe hyperbilirubinemia is associated with high rates of ABE and ET in this setting, and remains a significant contributor to neonatal admissions and mortality. To be impactful, FSPT, complemented with improved diagnostic facilities, should effectively curtail jaundice-related adverse outcomes in this and comparable settings.
authors.affiliation: Massey Street Children's Hospital, Lagos, Nigeria.
authors.forename: Abieyuwa A
authors.initials: AA
authors.lastname: Emokpae
authors.affiliation: Massey Street Children's Hospital, Lagos, Nigeria.
authors.forename: Cecilia A
authors.initials: CA
authors.lastname: Mabogunje
authors.affiliation: Massey Street Children's Hospital, Lagos, Nigeria.
authors.forename: Zainab O
authors.initials: ZO
authors.lastname: Imam
authors.affiliation: Centre for Healthy Start Initiative, 286A Corporation Drive, Dolphin Estate, Ikoyi, Lagos, Nigeria.
authors.forename: Bolajoko O
authors.initials: BO
authors.lastname: Olusanya
mesh_terms: D001663:Bilirubin / Q000378:metabolism; D001787:Blood Group Incompatibility / Q000378:metabolism; D005078:Exchange Transfusion, Whole Blood / Q000379:methods; D005260:Female; D006370:Heliotherapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000378:metabolism / Q000628:therapy*; D007647:Kernicterus / Q000378:metabolism / Q000628:therapy; D016015:Logistic Models; D008297:Male; D009549:Nigeria; D010789:Phototherapy / Q000009:adverse effects / Q000379:methods; D013472:Sunlight
chemical_list: D001663:Bilirubin